Enzymatica - Company presentation with CEO Fredrik Lindberg Recorded at our event ABGSC Investor Days in Stockholm, December 5th. [Läs mer på Introduc(https:/ Introduce. 10 december 2019. kommenterade Enzymatica AB

Bulletin from Annual General Meeting in Enzymatica AB (publ) Tue, May 05, 2020 16:20 CET. Today, on 5 May 2020, the Annual General Meeting (the ”AGM”) was held in Enzymatica AB (publ) (the ”Company”). Below follows a summary on the resolutions passed by the AGM. All resolutions were passed unanimously.

Enzymatica has established a strong position on the home market in Sweden with a market share for ColdZyme of 6.5%, based on rolling 12-month data at year-end 2019/2020. Enzymatica AB är ett life science-bolag som utvecklar och säljer medicintekniska produkter mot infektionsrelaterade sjukdomar. Produkterna är baserade på en barriärteknologi, som inkluderar marina enzymer. Övriga pågående uppdrag: Styrelseledamot i Aspekta AB, SIRA – Sveriges Investor Relationsförening, Wacht & Troy AB och Trolle-Wachtmeisters Medicinska Forskningsstiftelse. Utbildning: Fil kand i företagsekonomi och samhällskunskap. Innehav i Enzymatica: 250 000 aktier 100 000 teckningsoptioner Other directorships: Board member of Aspekta AB, the Swedish Investor Relations Association (SIRA), Wacht & Troy AB and Trolle-Wachtmeisters Medicinska Forskningsstiftelse. Education: BA in business administration and political science.

Enzymatica ab investor relations

Introduce är en av Sveriges ledande tjänster för IR med fokus på mindre börsnoterade bolag About Enzymatica AB Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. Investegate announcements from Enzymatica AB, Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany Notice of Extraordinary General Meeting in Enzymatica AB (publ) The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM") to be held on Monday November 5, 2018 … This information is information that Enzymatica AB “Investors cannot rely upon the bank getting Relations between Russia and the U.S. reached a new low this week after U.S 2021-03-31 Investor AB's Interim Management Statement January-March 2021 and Conference Call. 17 March.

2021-03-23 16:00:00 Notice to general meeting, Kallelse till årsstämma för Svedbergs i Dalstorp AB (publ.) 2021-02-25 14:00:00 Other information disclosed

Holdings in Enzymatica: 250 000 shares 100 000 warrants The Board of Directors of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue amounting to SEK 59.1 million, with preferential rights for existing The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the “Company”) are hereby invited to attend the annual general meeting (“AGM”) to be held on Tuesday 5 May 2020 at 2:30 p.m. CEST at Elite Hotel Ideon, Scheelevägen 27, 223 63 Lund. Registration for the AGM starts at 2:00 p.m.

Enzymatica AB, Ideon Science Park, 223 70 Lund Phone: +46 46 286 31 00, www.enzymatica.se, www.coldzyme.se 1 Press release 5 April, 2019 Notice of annual general meeting 2019 in Enzymatica AB (publ) The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the “Company”) are hereby

Investegate announcements from Enzymatica AB, Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany Notice of Extraordinary General Meeting in Enzymatica AB (publ) The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM") to be held on Monday November 5, 2018 … This information is information that Enzymatica AB “Investors cannot rely upon the bank getting Relations between Russia and the U.S. reached a new low this week after U.S 2021-03-31 Investor AB's Interim Management Statement January-March 2021 and Conference Call. 17 March.

As announced earlier Fr Enzymatica comments on article in Dagens Medicin Thu, Feb 11, 2021 16:02 CET. Dagens Medicin is critizing in an article on February 10, 2021 one of the clinical studies, the so called ColdPrev I, which is part of the clinical evaluation data supporting the benefits of the product, that Enzymatica uses in the marketing of ColdZyme®. Enzymatica säkerställer finansiering av verksamheten Enzymatica har erhållit ett brygglån från tre av sina huvudägare på sammanlagt 30 MSEK för finansiering av verksamheten 2018. Styrelsen arbetar samtidigt med finansiella rådgivare för att säkerställa den långsiktiga finansieringen av företagets internationella expansion. Enzymatica är ett life science-bolag som utvecklar och säljer medicintekniska produkter mot infektionsrelaterade sjukdomar. Produkterna baseras på barriärteknologi, som inkluderar marina enzymer. Bolagets första produkt är ColdZyme® Munspray som kan förhindra förkylning, och kan förkorta sjukdomsperioden. Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies.
Sven göran hedblom trafiklärare

Dec 23, 2020 OFFHUS, Offentliga Hus i Norden AB ENZY, Enzymatica AB but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, Dec 14, 2015 relations. We could predict a seasonality of revenues for at least a coming year, Enzymatica AB is the best seller of common cold products in 2014 in Sweden.

Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Enzymatica AB (publ) Organisationsnummer: 556719-9244 Post: Ideon Science Park, 223 70 LUND Investor Relations: christian@borsveckan.se 070-571 65 88 Enzymatica och STADA utökar avtalet för ViruProtect till Ryssland, Polen, Ukraina och CIS-länder tis, okt 13, 2020 08:30 CET. Enzymatica har utlicensierat exklusiva rättigheter till STADA att marknadsföra och sälja förkylningssprayen ViruProtect® (ColdZyme®) i Ryssland, Polen, Ukraina och 11 andra länder inom CIS och Centralasien. Recipharm, ett ledande CDMO-företag (Contract Development and Manufacturing Organisation), och Enzymatica, ett svenskt life science-bolag specialiserat på produkter med en skyddande barriär, har undertecknat ett utökat tillverkningsavtal för ColdZyme®.
Vad betyder b2b

svolder aktiebolag
monopol pengar hur mycket
gravidmassage friskvard
urininkontinens aldre
vart ligger lund

STOCKHOLM, March 29, 2021 /PRNewswire/ -- The Board of Directors of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue amounting to SEK 59.1 million, with preferential rights for existing shareholders, by exercising the authorization of a new rights issue from the Annaul General Meeting 2020 (the "Rights issue").

Source: Holdings by Modular Finance AB . Search. English (United Kingdom) en. German (Germany) Deutsch (DE). 123. About STADA · Products · Investor Relations · Media · Stories · Career · Contact.

Other directorships: Board member of Aspekta AB, the Swedish Investor Relations Association (SIRA), Wacht & Troy AB and Trolle-Wachtmeisters Medicinska Forskningsstiftelse. Education: BA in business administration and political science. Holdings in Enzymatica: 250 000 shares 100 000 warrants

Shelton Group Investor Relations Leanne Sievers or Jeff Schreiner Tel: 949-224-3874 | 512-243-8976 Investor relations . Annie Ho. Head of Investor Relations +46 8 585 922 69 annie.ho@swedbank.com. All IR contacts We use cookies to make swedbank.com work optimally.

Notice of Annual General Meeting 2021 in Enzymatica AB (publ). He has worked at, among others, Atos Medical AB and Industrifonden, and of Enzymatica AB, CEO of Occlutech International AB and CFO of CellaVision AB. For the purposes of this representation, the expression an “offer” in relation to any of the “Cornerstone Investors” refers to Backahill Utveckling AB, Catella Fondförvaltning AB, Other current appointments: Enzymatica AB (publ), 10 feb 2015 Fredrik Lindberg, VD Enzymatica AB. Telefon: 046-286 31 00. E-post: ir@ enzymatica.se.